[Federal Register Volume 91, Number 32 (Wednesday, February 18, 2026)]
[Notices]
[Page 7542]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2026-03144]
=======================================================================
-----------------------------------------------------------------------
NUCLEAR REGULATORY COMMISSION
Advisory Committee on the Medical Uses of Isotopes: Charter
Renewal
AGENCY: Nuclear Regulatory Commission.
ACTION: Notice of renewal of the Charter of the Advisory Committee on
the Medical Uses of Isotopes.
-----------------------------------------------------------------------
The U.S. Nuclear Regulatory Commission (NRC) has determined that
renewal of the charter for the Advisory Committee of the Medical Uses
of Isotopes (ACMUI) until February 27, 2028, is in the public interest
in connection with duties imposed on the Commission by law. This action
is being taken in accordance with the Federal Advisory Committee Act,
as amended, 5 U.S.C. chapter 10, after consultation with the Committee
Management Secretariat, General Services Administration.
The purpose of the ACMUI is to provide advice to the NRC on policy
and technical issues that arise in regulating the medical use of
byproduct material for diagnosis and therapy. Responsibilities include
providing guidance and comments on current and proposed NRC regulations
and regulatory guidance concerning medical use; evaluating certain non-
routine uses of byproduct material for medical use; and evaluating
training and experience of proposed authorized users. The members are
involved in preliminary discussions of major issues in determining the
need for changes in NRC policy and regulation to ensure the continued
safe use of byproduct material. Each member provides technical
assistance in his/her specific area(s) of expertise, particularly with
respect to emerging technologies. Members also provide guidance as to
NRC's role in relation to the responsibilities of other Federal
agencies as well as of various professional organizations and boards.
ACMUI is in the public interest because the advice received from it
helps the NRC ensure the safety of the public, patients, and workers
who might be exposed to radiation from such medical usage.
To ensure the committee has the necessary expertise and fairly
balanced membership, members are selected based on demonstrated
professional qualifications and expertise in both scientific and non-
scientific disciplines including nuclear medicine; nuclear cardiology;
radiation therapy; medical physics; nuclear pharmacy; State medical
regulation; patient's rights and care; health care administration; and
Food and Drug Administration regulation. Because the NRC does not have
this expertise on staff, it leverages the Committee's well-recognized
specialists from different parts of the United States to provide advice
and expert opinion on standards and guides used in diagnostic and
therapeutic practices in the United States. The NRC continues to
emphasize improving performance of medical use licensees and ACMUI's
experts will continue to be needed to assist the Commission in this
area. To develop and maintain a cost-effective and less burdensome in-
house capability to match the quality and quantity of expert advice
embodied in the ACMUI is not viable. A summary of specific
accomplishments of ACMUI over the last charter term (February 2024-
February 2026) can be reviewed at https://www.nrc.gov/about-nrc/regulatory/advisory/acmui/recomm-actions.
ACMUI is one of three advisory committees at the NRC. The others
are the Advisory Committee on Reactor Safeguards and the Licensing
Support Network Advisory Review Panel.
Estimated costs for ACMUI include federal personnel and other costs
of $366,000; payments to members of $70,000 for 13 members; and
reimbursable costs of $19,000.
FOR FURTHER INFORMATION CONTACT: Sarah Hoenig, Office of Nuclear
Material Safety and Safeguards, U.S. Nuclear Regulatory Commission,
Washington, DC 20555; Email: [email protected].
Dated at Rockville, Maryland this 13th day of February, 2026.
For the U.S. Nuclear Regulatory Commission.
Russell E. Chazell,
Federal Advisory Committee Management Officer.
[FR Doc. 2026-03144 Filed 2-17-26; 8:45 am]
BILLING CODE 7590-01-P